{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:13:48Z","timestamp":1788480828335,"version":"build-2803163510"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00228-020-03048-y","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T10:02:42Z","timestamp":1609668162000},"page":"795-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-1901","authenticated-orcid":false,"given":"Anna","family":"Basi\u0144ska-Szafra\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"3048_CR1","volume-title":"Final act of the United Nations conference for the adoption of a protocol on psychotropic substance","author":"Convention on Psychotropic Substances","year":"1971","unstructured":"Convention on Psychotropic Substances (1971) Final act of the United Nations conference for the adoption of a protocol on psychotropic substance. United Nations, Vienna"},{"key":"3048_CR2","volume-title":"The effects of tranquilization: benzodiazepine use in Canada","author":"R Cooperstock","year":"1982","unstructured":"Cooperstock R, Hill J (1982) The effects of tranquilization: benzodiazepine use in Canada. Health and Welfare, Ottawa"},{"key":"3048_CR3","first-page":"1","volume":"21","author":"Committee on Safety of Medicines","year":"1988","unstructured":"Committee on Safety of Medicines (1988) Benzodiazepines, dependence and withdrawal symptoms. Curr Probl 21:1\u20132","journal-title":"Curr Probl"},{"key":"3048_CR4","volume-title":"Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder","author":"A McIntosh","year":"2004","unstructured":"McIntosh A, Cohen A, Turnbull N et al (2004) Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. National Collaborating Centre for primary care, Sheffield"},{"key":"3048_CR5","unstructured":"National Institute for Health and Clinical Excellence (2011) Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline, www.nice.org.uk\/guidance\/cg113. Accessed 20 May 2019"},{"key":"3048_CR6","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2012) 2012 annual report on the state of the drugs problem in Europe. Lisbon, Portugal, p 84"},{"key":"3048_CR7","unstructured":"Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2011) The TEDS report: substance abuse treatment admissions for abuse of benzodiazepines. Rockville, USA"},{"issue":"11","key":"3048_CR8","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1360-0443.2010.03177.x","volume":"105","author":"M Liebrenz","year":"2010","unstructured":"Liebrenz M, Boesch L, Stohler R et al (2010) Benzodiazepine dependence: when abstinence is not an option. Addiction 105(11):1877\u20131878","journal-title":"Addiction"},{"issue":"suppl 2","key":"3048_CR9","first-page":"28","volume":"66","author":"CP O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CP (2005) Benzodiazepine use, abuse and dependence. J Clin Psychiatry 66(suppl 2):28\u201333","journal-title":"J Clin Psychiatry"},{"key":"3048_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0022-3956(90)90039-S","volume":"24","author":"RL DuPont","year":"1990","unstructured":"DuPont RL (1990a) A practical approach to benzodiazepine discontinuation. J Psychiatr Res 24:81\u201390. https:\/\/doi.org\/10.1016\/0022-3956(90)90039-S","journal-title":"J Psychiatr Res"},{"key":"3048_CR11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4088\/JCP.v61n0308","volume":"61","author":"DA Charney","year":"2000","unstructured":"Charney DA, Paraherakis AM, Gill KJ (2000) The treatment of sedative-hypnotic dependence: evaluating clinical predictors of outcome. J Clin Psychiatry 61:190\u2013195","journal-title":"J Clin Psychiatry"},{"key":"3048_CR12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.addbeh.2004.01.001","volume":"29","author":"KP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor KP, Marchand A, Belanger L et al (2004) Psychological distress and adaptional problems associated with benzodiazepine withdrawal and outcome: a replication. Addict Behav 29:583\u2013593","journal-title":"Addict Behav"},{"key":"3048_CR13","doi-asserted-by":"publisher","unstructured":"Sofin Y, Danker-Hopfe H, Gooren T et al (2017) Predicting inpatient detoxification outcome of alcohol and drug dependent patients: the influence of sociodemographic environment, motivation, impulsivity, and medical comorbidities. J Addict. https:\/\/doi.org\/10.1155\/2017\/6415831","DOI":"10.1155\/2017\/6415831"},{"issue":"1\u20132","key":"3048_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0740-5472(91)90023-4","volume":"8","author":"H Ashton","year":"1991","unstructured":"Ashton H (1991) Protracted withdrawal syndromes from benzodiazepines. J Subst Abus Treat 8(1\u20132):19\u201328. https:\/\/doi.org\/10.1016\/0740-5472(91)90023-4","journal-title":"J Subst Abus Treat"},{"issue":"13","key":"3048_CR15","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1177\/1049732317728053","volume":"27","author":"AM Fixsen","year":"2017","unstructured":"Fixsen AM, Ridge D (2017) Stories of hell and healing: internet Users\u2019 construction of benzodiazepine distress and withdrawal. Qual Health Res 27(13):2030\u20132041. https:\/\/doi.org\/10.1177\/1049732317728053","journal-title":"Qual Health Res"},{"key":"3048_CR16","unstructured":"Ashton HC (2002a) Slow withdrawal schedules. In: benzodiazepines: how they work and how to withdraw (the Ashton manual). https:\/\/www.benzo.org.uk\/manual\/bzsched.htm (rev. 2013). Accessed 10 Apr 2019"},{"issue":"1","key":"3048_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/0023210-200923010-00002","volume":"23","author":"M Lader","year":"2009","unstructured":"Lader M, Tylee A, Donoghue J (2009) Withdrawing benzodiazepines in primary care. CNS Drugs 23(1):19\u201334. https:\/\/doi.org\/10.2165\/0023210-200923010-00002","journal-title":"CNS Drugs"},{"key":"3048_CR18","doi-asserted-by":"publisher","unstructured":"Denis C, Fats\u00e9as M, Lavie E et al (2006) Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005194.pub2. Accessed 19 June 2019","DOI":"10.1002\/14651858.CD005194.pub2"},{"issue":"5","key":"3048_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/2045125317753340","volume":"8","author":"D Fluyau","year":"2018","unstructured":"Fluyau D, Revadigar N, Manobianco BE (2018) Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 8(5):147\u2013168","journal-title":"Ther Adv Psychopharmacol"},{"key":"3048_CR20","doi-asserted-by":"publisher","unstructured":"Baandrup L, Ebdrup BH, Rasmussen J, Lindschou J, Gluud C, Glenth\u00f8j B (2019) Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users (review). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011481.pub2. Accessed 10 June 2019","DOI":"10.1002\/14651858.CD011481.pub2"},{"key":"3048_CR21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/bmj.300.6734.1241","volume":"300","author":"A Holton","year":"1990","unstructured":"Holton A, Tyrer P (1990) Five year outcome in patients withdrawn from long term treatment with diazepam. Br Med J 300:1241\u20131242","journal-title":"Br Med J"},{"key":"3048_CR22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1192\/bjp.178.4.317","volume":"178","author":"F Zitman","year":"2001","unstructured":"Zitman F, Couvee J (2001) Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch chronic benzodiazepine working group. Br J Psychiatry 178:317\u2013324","journal-title":"Br J Psychiatry"},{"key":"3048_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brat.2003.12.002","volume":"43","author":"CM Morin","year":"2005","unstructured":"Morin CM, Belanger L, Bastien C et al (2005) Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse. Behav Res Ther 43:1\u201314","journal-title":"Behav Res Ther"},{"issue":"6424","key":"3048_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/bmj.288.6424.1135","volume":"288","author":"H Ashton","year":"1984","unstructured":"Ashton H (1984) Benzodiazepine withdrawal: an unfinished story. BMJ (Br Med J) 288(6424):1135\u20131140. https:\/\/doi.org\/10.1136\/bmj.288.6424.1135","journal-title":"BMJ (Br Med J)"},{"issue":"10","key":"3048_CR25","doi-asserted-by":"publisher","first-page":"e0163224","DOI":"10.1371\/journal.pone.0163224","volume":"11","author":"DF Niedrig","year":"2016","unstructured":"Niedrig DF, Hoppe L, M\u00e4chler S, Russmann H, Russmann S (2016) Benzodiazepine use during hospitalization: automated identification of potential medication errors and systematic assessment of preventable adverse events. PLoS ONE 11(10):e0163224. https:\/\/doi.org\/10.1371\/journal.pone.0163224","journal-title":"PLoS ONE"},{"key":"3048_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1517\/17425255.2013.759209","volume":"9","author":"AC Altamura","year":"2013","unstructured":"Altamura AC, Moliterno D, Paletta S, Maffini M, Mauri MC, Bareggi S (2013) Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol 9:423\u2013440. https:\/\/doi.org\/10.1517\/17425255.2013.759209","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"3048_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1124\/jpet.111.183285","volume":"339","author":"MM Reidenberg","year":"2011","unstructured":"Reidenberg MM (2011) Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 339(2):324\u2013328. https:\/\/doi.org\/10.1124\/jpet.111.183285","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl.1","key":"3048_CR28","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1186\/1744-859X-9-S1-S156","volume":"9","author":"A Basi\u0144ska","year":"2010","unstructured":"Basi\u0144ska A, Jamro\u017cy A, Habrat B (2010) Prolonged benzodiazepine elimination in addicted patients as a reason of early post-detoxification relapses. Ann General Psychiatry 9(suppl.1):S156","journal-title":"Ann General Psychiatry"},{"key":"3048_CR29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","volume":"18","author":"H Ashton","year":"2005","unstructured":"Ashton H (2005) The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatr 18:249\u2013255","journal-title":"Curr Opin Psychiatr"},{"key":"3048_CR30","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M (2017) Treatment of benzodiazepine dependence. N Engl J Med 376:1147\u20131157","journal-title":"N Engl J Med"},{"key":"3048_CR31","doi-asserted-by":"crossref","unstructured":"Guina J, Merrill B (2018) Benzodiazepines II: waking up on sedatives. Providing optimal care when Inheriting benzodiazepine prescriptions in transfer patients. J Clin Med. 10.3390\/jcm7020020. Accessed 10 May 2019","DOI":"10.3390\/jcm7020020"},{"key":"3048_CR32","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","volume":"106","author":"M Lader","year":"2011","unstructured":"Lader M (2011) Benzodiazepines revisited \u2013 will we ever learn? Addiction 106:2086\u20132109. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03563.x","journal-title":"Addiction"},{"issue":"1","key":"3048_CR33","first-page":"139","volume":"58","author":"NS Miller","year":"1998","unstructured":"Miller NS, Gold MS (1998) Management of withdrawal syndromes and relapse prevention in drug and alcohol dependence. Am Fam Physician 58(1):139\u2013146","journal-title":"Am Fam Physician"},{"key":"3048_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-015-0019-8","volume":"16","author":"AS Pollmann","year":"2015","unstructured":"Pollmann AS, Murphy AL, Bergman JC et al (2015) Deprescribing the benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 16:19. https:\/\/doi.org\/10.1186\/s40360-015-0019-8","journal-title":"BMC Pharmacol Toxicol"},{"key":"3048_CR35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.156.3.406","volume":"156","author":"T Cantopher","year":"1990","unstructured":"Cantopher T, Olivieri S, Cleave N et al (1990) Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry 156:406\u2013411","journal-title":"Br J Psychiatry"},{"key":"3048_CR36","first-page":"290","volume":"23","author":"P Lemoine","year":"1997","unstructured":"Lemoine P, Touchon J, Billardon M (1997) Withdrawal of long-term administered lorazepam using 6 different plans. A placebo controlled study. Encephale 23:290\u2013299","journal-title":"Encephale"},{"key":"3048_CR37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0011-393X(05)80679-4","volume":"54","author":"G Gerra","year":"1993","unstructured":"Gerra G, Marcato A, Caccavari R et al (1993) Effectiveness of flumazenil (RO 15-1788) in the treatment of benzodiazepine withdrawal. Curr Ther Res 54:580\u2013587. https:\/\/doi.org\/10.1016\/S0011-393X(05)80679-4","journal-title":"Curr Ther Res"},{"key":"3048_CR38","first-page":"97","volume":"59","author":"SE File","year":"1993","unstructured":"File SE, Andrews N (1993) Benzodiazepine withdrawal: behavioural pharmacology and neurochemical changes. Biochem Soc Symp 59:97\u2013106","journal-title":"Biochem Soc Symp"},{"key":"3048_CR39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s002130050278","volume":"131","author":"L Saxon","year":"1997","unstructured":"Saxon L, Hjemdahl P, Hiltunen AJ et al (1997) Effects of flumazenil in the treatment of benzodiazepine withdrawal \u2013 a double-blind pilot study. Psychopharmacology 131:153\u2013160","journal-title":"Psychopharmacology"},{"issue":"2","key":"3048_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bcp.12023","volume":"77","author":"SD Hood","year":"2014","unstructured":"Hood SD, Norman A, Hince DA et al (2014) Benzodiazepine dependence and its treatment with low dose flumazenil. Brit J Clin Pharmacol 77(2):285\u2013294. https:\/\/doi.org\/10.1111\/bcp.12023","journal-title":"Brit J Clin Pharmacol"},{"key":"3048_CR41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/1355621021000005973","volume":"7","author":"G Gerra","year":"2002","unstructured":"Gerra G, Zaimovic A, Giusti F et al (2002) Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol 7:385\u2013395","journal-title":"Addict Biol"},{"issue":"3","key":"3048_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.psychres.2012.02.008","volume":"198","author":"G Quaglio","year":"2012","unstructured":"Quaglio G, Pattaro C, Gerra G et al (2012) High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam. Psychiatry Res 198(3):457\u2013462. https:\/\/doi.org\/10.1016\/j.psychres.2012.02.008","journal-title":"Psychiatry Res"},{"issue":"10","key":"3048_CR43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1177\/0269881116647505","volume":"30","author":"M Faccini","year":"2016","unstructured":"Faccini M, Leone R, Opri S et al (2016) Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. J Psychopharmacol 30(10):1047\u20131053. https:\/\/doi.org\/10.1177\/0269881116647505","journal-title":"J Psychopharmacol"},{"issue":"2","key":"3048_CR44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s002130051161","volume":"147","author":"MZ Mintzer","year":"1999","unstructured":"Mintzer MZ, Stoller KB, Griffiths RR (1999) A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology 147(2):200\u2013209","journal-title":"Psychopharmacology"},{"issue":"7\u20138","key":"3048_CR45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/106002808602000702","volume":"20","author":"PJ Perry","year":"1986","unstructured":"Perry PJ, Alexander B (1986) Sedative\/hypnotic dependence: patient stabilization, tolerance testing, and withdrawal. Drug Intell Clin Pharm 20(7\u20138):532\u2013537","journal-title":"Drug Intell Clin Pharm"},{"key":"3048_CR46","first-page":"600","volume":"152","author":"RL DuPont","year":"1990","unstructured":"DuPont RL (1990b) A physician's guide to discontinuing benzodiazepine therapy. West J Med 152:600\u2013603","journal-title":"West J Med"},{"key":"3048_CR47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0376-8716(91)90049-5","volume":"29","author":"PM Brenner","year":"1991","unstructured":"Brenner PM, Wolf B, Rechlin T et al (1991) Benzodiazepine dependence: detoxification under standardized conditions. Drug Alcohol Depend 29:195\u2013204","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"3048_CR48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/00952990802149021","volume":"34","author":"B Croissant","year":"2008","unstructured":"Croissant B, Grosshans M, Diehl A et al (2008) Oxcarbazepine in rapid benzodiazepine detoxification. Am J Drug Alcohol Abuse 34(5):534\u2013540. https:\/\/doi.org\/10.1080\/00952990802149021","journal-title":"Am J Drug Alcohol Abuse"},{"key":"3048_CR49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1192\/bjp.158.4.511","volume":"158","author":"SM Murphy","year":"1991","unstructured":"Murphy SM, Tyrer P (1991) A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry 158:511\u2013516","journal-title":"Br J Psychiatry"},{"issue":"suppl","key":"3048_CR50","first-page":"22","volume":"48","author":"JB Herman","year":"1987","unstructured":"Herman JB, Brotman A, Rosenbaum JE (1987) Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. J Clin Psychiatry 48(suppl):22\u201328","journal-title":"J Clin Psychiatry"},{"key":"3048_CR51","first-page":"206","volume":"51","author":"SC Risse","year":"1990","unstructured":"Risse SC, Whitters A, Burke J et al (1990) Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry 51:206\u2013209","journal-title":"J Clin Psychiatry"},{"key":"3048_CR52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/02791072.1993.10472289","volume":"25","author":"R Malcolm","year":"1993","unstructured":"Malcolm R, Brady KT, Johnson AL et al (1993) Types of benzodiazepines abused by chemically dependent inpatients. J Psychoactive Drugs 25:315\u2013319","journal-title":"J Psychoactive Drugs"},{"issue":"9","key":"3048_CR53","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2105\/AJPH.83.9.1300","volume":"83","author":"DD Hallfors","year":"1993","unstructured":"Hallfors DD, Saxe L (1993) The dependence potential of short half-life benzodiazepines: a meta-analysis. Am J Public Health 83(9):1300\u20131304","journal-title":"Am J Public Health"},{"issue":"11","key":"3048_CR54","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","volume":"89","author":"H P\u00e9tursson","year":"1994","unstructured":"P\u00e9tursson H (1994) The benzodiazepine withdrawal syndrome. Addiction 89(11):1455\u20131459","journal-title":"Addiction"},{"key":"3048_CR55","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00004714-198604000-00023","volume":"6","author":"SJ Kantor","year":"1986","unstructured":"Kantor SJ (1986) A difficult alprazolam withdrawal. J Clin Psychopharmacol 6:124\u2013125","journal-title":"J Clin Psychopharmacol"},{"key":"3048_CR56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/106002808602001102","volume":"20","author":"JL Browne","year":"1986","unstructured":"Browne JL, Hauge KJ (1986) A review of alprazolam withdrawal. Drug Intell Clin Pharm 20:837\u2013841","journal-title":"Drug Intell Clin Pharm"},{"key":"3048_CR57","first-page":"344","volume":"46","author":"RB Zipursky","year":"1985","unstructured":"Zipursky RB, Baker RW, Zimmer B (1985) Alprazolam withdrawal delirium unresponsive to diazepam: case report. J Clin Psychiatry 46:344\u2013345","journal-title":"J Clin Psychiatry"},{"key":"3048_CR58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0740-5472(94)90042-6","volume":"11","author":"MH Closser","year":"1994","unstructured":"Closser MH, Brower KJ (1994) Treatment of alprazolam withdrawal with chlordiazepoxide substitution and taper. J Subst Abus Treat 11:319\u2013323","journal-title":"J Subst Abus Treat"},{"issue":"suppl","key":"3048_CR59","first-page":"43","volume":"48","author":"JH Albeck","year":"1987","unstructured":"Albeck JH (1987) Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam. J Clin Psychiatry 48(suppl):43\u20134914","journal-title":"J Clin Psychiatry"},{"issue":"suppl","key":"3048_CR60","first-page":"47","volume":"51","author":"JF Patterson","year":"1990","unstructured":"Patterson JF (1990) Withdrawal from alprazolam dependency using clonazepam: clinical observations. J Clin Psychiatry 51(suppl):47\u201349","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"3048_CR61","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/clpt.1983.256","volume":"34","author":"EM Sellers","year":"1983","unstructured":"Sellers EM, Naranjo CA, Harrison M et al (1983) Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther 34(6):822\u2013826","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3048_CR62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/clpt.1984.214","volume":"36","author":"M Harrison","year":"1984","unstructured":"Harrison M, Busto U, Naranjo CA et al (1984) Diazepam tapering in detoxification for high-dose benzodiazepine abuse. Clin Pharmacol Ther 36(4):527\u2013533","journal-title":"Clin Pharmacol Ther"},{"key":"3048_CR63","unstructured":"Ashton H (2002b) Benzodiazepine equivalence tables. In: Benzodiazepines: how do they act and how to withdraw. The Ashton Manual (www.benzo.org.uk\/bzequiv.htm. Rev. 2007. Accessed 10 Apr 2018"},{"key":"3048_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","volume":"118","author":"J Riss","year":"2008","unstructured":"Riss J, Cloyd J, Gates J et al (2008) Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 118:69\u201386. https:\/\/doi.org\/10.1111\/j.1600-0404.2008.01004.x","journal-title":"Acta Neurol Scand"},{"key":"3048_CR65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imj.12315","volume":"44","author":"MM Islam","year":"2014","unstructured":"Islam MM, Conigrave KM, Day CA et al (2014) Twenty-year trends in benzodiazepine dispensing in the Australian population. Intern Med J 44:57\u201364","journal-title":"Intern Med J"},{"key":"3048_CR66","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5694\/mja12.10986","volume":"198","author":"AC Rintoul","year":"2013","unstructured":"Rintoul AC, Dobbin MD, Nielsen S et al (2013) Recent increase in detection of alprazolam in Victorian heroin-related deaths. Med J Aust 198:206\u2013209","journal-title":"Med J Aust"},{"key":"3048_CR67","unstructured":"Lowry F (2014) Benzodiazepine addiction meds the same, but different? Medscape, www.medscape.com\/viewarticle\/823979. Accessed 10 May 2018"},{"issue":"3","key":"3048_CR68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/070674370104600315","volume":"46","author":"D Crockford","year":"2001","unstructured":"Crockford D, White WD, Campbell B (2001) Gabapentin use in benzodiazepine dependence and detoxification. Can J Psychiatr 46(3):287","journal-title":"Can J Psychiatr"},{"issue":"4","key":"3048_CR69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5114\/ppn.2019.92491","volume":"28","author":"U Cie\u015blak","year":"2019","unstructured":"Cie\u015blak U, Basi\u0144ska-Szafra\u0144ska A (2019) Steering the pharmacological treatment along different metabolic pathways in response to outlying complicated benzodiazepine withdrawal. Adv Psychiatry Neurol (Post\u0119py Psychiatrii i Neurol) 28(4):283\u2013290. https:\/\/doi.org\/10.5114\/ppn.2019.92491","journal-title":"Adv Psychiatry Neurol (Post\u0119py Psychiatrii i Neurol)"},{"issue":"1","key":"3048_CR70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0740-5472(90)90036-P","volume":"7","author":"NV Ravi","year":"1990","unstructured":"Ravi NV, Maany I, Burke WM et al (1990) Detoxification with phenobarbital of alprazolam-dependent polysubstance abusers. J Subst Abus Treat 7(1):55\u201358","journal-title":"J Subst Abus Treat"},{"key":"3048_CR71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10401239309148974","volume":"5","author":"M Sullivan","year":"1993","unstructured":"Sullivan M, Toshima M, Lynn P et al (1993) Phenobarbital versus clonazepam for sedative-hypnotic taper in chronic pain patients: a pilot study. Ann Clin Psychiatry 5:123\u2013128","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"3048_CR72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jsat.2011.12.011","volume":"43","author":"SS Kawasaki","year":"2012","unstructured":"Kawasaki SS, Jacapraro JS, Rastegar DA (2012) Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. J Subst Abus Treat 43(3):331\u2013334. https:\/\/doi.org\/10.1016\/j.jsat.2011.12.011","journal-title":"J Subst Abus Treat"},{"key":"3048_CR73","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent expert working group (2017) drug misuse and dependence: UK guidelines on clinical management. London: Department of Health https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf"},{"key":"3048_CR74","unstructured":"The JPS Behavioral Health Virtual Resource (2014) Prescribing and tapering benzodiazepines. Virtual Guidance Program. E-Resource, https:\/\/www.jpshealthnet.org\/sites\/default\/files\/prescribing_and_tapering_benzodiazepines.pdf. Accessed 15 June 2019"},{"issue":"5","key":"3048_CR75","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B (2015) Management of benzodiazepine misuse and dependence. Aust Prescr 38(5):152\u2013155. https:\/\/doi.org\/10.18773\/austprescr.2015.055","journal-title":"Aust Prescr"},{"key":"3048_CR76","unstructured":"Kane SP (2017) Equivalent benzodiazepine calculator. ClinCalc LLC https:\/\/clincalc.com\/Benzodiazepine. Accessed 3 June 2019"},{"key":"3048_CR77","first-page":"113","volume":"139","author":"EM Sellers","year":"1988","unstructured":"Sellers EM (1988) Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. CMAJ (Can Med Assoc J) 139:113\u2013120","journal-title":"CMAJ (Can Med Assoc J)"},{"issue":"10","key":"3048_CR78","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/106002808501901010","volume":"19","author":"WS Bond","year":"1985","unstructured":"Bond WS, Berwish NJ, Swift B (1985) Severe withdrawal syndrome after substitution of a short-acting benzodiazepine for a long-acting benzodiazepine. Drug Intell Clin Pharm 19(10):742\u2013744","journal-title":"Drug Intell Clin Pharm"},{"key":"3048_CR79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1752-1947-5-207","volume":"5","author":"H Bosshart","year":"2011","unstructured":"Bosshart H (2011) Withdrawal-induced delirium associated with a benzodiazepine switch: a case report. J Med Case Rep 5:207. https:\/\/doi.org\/10.1186\/1752-1947-5-207","journal-title":"J Med Case Rep"},{"key":"3048_CR80","unstructured":"Merriam-Webster Medical Dictionary (2019) Loading Dose Medical Definition, https:\/\/www.merriam-webster.com\/medical\/loading%20dose. Accessed 10 July 2019"},{"issue":"2","key":"3048_CR81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.20882\/adicciones.1058","volume":"30","author":"C Oliveras","year":"2018","unstructured":"Oliveras C, Fortea A, Espinosa L et al (2018) \u201cDiazepam loading\u201d: \u00bfcan a strategy for preventing alcohol withdrawal be used to treat benzodiazepine use disorder? Adicciones 30(2):155\u2013157. https:\/\/doi.org\/10.20882\/adicciones.1058","journal-title":"Adicciones"},{"key":"3048_CR82","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/oxfordjournals.alcalc.a008147","volume":"31","author":"D Wasilewski","year":"1996","unstructured":"Wasilewski D, Matsumoto H, Kur E et al (1996) Assessment of diazepam loading dose therapy of delirium tremens. Alcohol Alcohol 31:273\u2013278","journal-title":"Alcohol Alcohol"},{"key":"3048_CR83","first-page":"1","volume":"2","author":"F Frare","year":"2000","unstructured":"Frare F, Perugi G (2000) Managing benzodiazepine withdrawal. Heroin Addict Relat Clin Probl 2:1\u201318","journal-title":"Heroin Addict Relat Clin Probl"},{"issue":"4","key":"3048_CR84","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s002130050789","volume":"140","author":"R Pat-Horenczyk","year":"1998","unstructured":"Pat-Horenczyk R, Hacohen D, Herer P et al (1998) The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology 140(4):450\u2013457. https:\/\/doi.org\/10.1007\/s002130050789","journal-title":"Psychopharmacology"},{"issue":"12","key":"3048_CR85","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1176\/appi.ajp.157.12.1973","volume":"157","author":"K Rickels","year":"2000","unstructured":"Rickels K, DeMartinis N, Garcia-Espana F et al (2000) Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry 157(12):1973\u20131979","journal-title":"Am J Psychiatry"},{"issue":"4","key":"3048_CR86","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0269881111405360","volume":"26","author":"SJ Hadley","year":"2012","unstructured":"Hadley SJ, Mandel FS, Schweizer E (2012) Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 26(4):461\u2013470. https:\/\/doi.org\/10.1177\/0269881111405360","journal-title":"J Psychopharmacol"},{"key":"3048_CR87","unstructured":"Bourne D (2014) Multiple oral dose administration. In: basic pharmacokinetics, ch.15. https:\/\/www.boomer.org\/c\/p4\/c15\/c1501.php. Accessed 15 May 2019"},{"issue":"11","key":"3048_CR88","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00228-001-0387-4","volume":"57","author":"M Petrovic","year":"2002","unstructured":"Petrovic M, Pevernagie D, Mariman A, Van Maele G, Afschrift M (2002) Fast withdrawal from benzodiazepines in geriatric inpatients: a randomised double-blind, placebo-controlled trial. Eur J Clin Pharmacol 57(11):759\u2013764. https:\/\/doi.org\/10.1007\/s00228-001-0387-4","journal-title":"Eur J Clin Pharmacol"},{"key":"3048_CR89","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0740-5472(91)90022-3","volume":"8","author":"B Alexander","year":"1991","unstructured":"Alexander B, Perry PJ (1991) Detoxification from benzodiazepines: schedules and strategies. J Subst Abus Treat 8:9\u201317. https:\/\/doi.org\/10.1016\/0740-5472(91)90022-3","journal-title":"J Subst Abus Treat"},{"key":"3048_CR90","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pnpbp.2005.08.015","volume":"30","author":"P Lemoine","year":"2006","unstructured":"Lemoine P, Kermadi I, Garcia-Acosta S et al (2006) Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Prog Neuro-Psychoph 30:131\u2013137. https:\/\/doi.org\/10.1016\/j.pnpbp.2005.08.015","journal-title":"Prog Neuro-Psychoph"},{"key":"3048_CR91","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1192\/bjp.189.3.213","volume":"189","author":"RC Voshaar","year":"2006","unstructured":"Voshaar RC, Couvee JE, van Balkom AJ et al (2006) Strategies for discontinuing long-term benzodiazepine use: meta analysis. Br J Psychiatry 189:213\u2013220","journal-title":"Br J Psychiatry"},{"key":"3048_CR92","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/09595230100100615","volume":"22","author":"C McGregor","year":"2003","unstructured":"McGregor C, Machin A, White JM (2003) In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug Alcohol Rev 22:175\u2013180","journal-title":"Drug Alcohol Rev"},{"key":"3048_CR93","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/02791072.1991.10472575","volume":"23","author":"R Ries","year":"1991","unstructured":"Ries R, Cullison S, Horn R et al (1991) Benzodiazepine withdrawal: clinicians' ratings of carbamazepine treatment versus traditional taper methods. J Psychoactive Drugs 23:73\u201376. https:\/\/doi.org\/10.1080\/02791072.1991.10472575","journal-title":"J Psychoactive Drugs"},{"key":"3048_CR94","first-page":"1","volume":"22","author":"A Azparren","year":"2014","unstructured":"Azparren A, Garcia I (2014) Strategies for discontinuing benzodiazepines. Drug Therapeut Bull Navarre 22:1\u201312","journal-title":"Drug Therapeut Bull Navarre"},{"issue":"6292","key":"3048_CR95","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bmj.283.6292.643","volume":"283","author":"H P\u00e9tursson","year":"1981","unstructured":"P\u00e9tursson H, Lader MH (1981) Withdrawal from long-term benzodiazepine treatment. BMJ (Br Med J) 283(6292):643\u2013645. https:\/\/doi.org\/10.1136\/bmj.283.6292.643","journal-title":"BMJ (Br Med J)"},{"key":"3048_CR96","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/1756-0500-5-684","volume":"5","author":"C Lopez-Peig","year":"2012","unstructured":"Lopez-Peig C, Mundet X, Casabella B et al (2012) Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain. BMC Res Notes 5:684. https:\/\/doi.org\/10.1186\/1756-0500-5-684","journal-title":"BMC Res Notes"},{"key":"3048_CR97","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","volume":"41","author":"K Rickels","year":"1990","unstructured":"Rickels K, Schweizer E, Case WG, Greenblatt DJ (1990) Long-term therapeutic use of benzodiazepines: effects of abrupt discontinuation. Arch Gen Psychiatry 41:899\u2013907","journal-title":"Arch Gen Psychiatry"},{"key":"3048_CR98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/clpt.1981.129","volume":"30","author":"GM Robinson","year":"1981","unstructured":"Robinson GM, Sellers EM, Janecek E (1981) Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique. Clin Pharmacol Ther 30:71\u201376","journal-title":"Clin Pharmacol Ther"},{"key":"3048_CR99","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1358\/dot.2004.40.7.850478","volume":"40","author":"DF Zullino","year":"2004","unstructured":"Zullino DF, Khazaal Y, Hattenschwiler J et al (2004) Anticonvulsant drugs in the treatment of substance withdrawal. Drug Today 40:603\u2013619","journal-title":"Drug Today"},{"issue":"12","key":"3048_CR100","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1176\/ajp.151.12.1760","volume":"151","author":"E Klein","year":"1994","unstructured":"Klein E, Colin V, Stolk J et al (1994) Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry 151(12):1760\u20131766","journal-title":"Am J Psychiatry"},{"key":"3048_CR101","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archpsyc.1991.01810290060012","volume":"8","author":"E Schweizer","year":"1991","unstructured":"Schweizer E, Rickels K, Case W et al (1991) Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry 8:448\u2013452","journal-title":"Arch Gen Psychiatry"},{"key":"3048_CR102","first-page":"301","volume":"33","author":"E DiConstanzo","year":"1992","unstructured":"DiConstanzo E, Rovea A (1992) The prophylaxis of benzodiazepine withdrawal syndrome in the elderly: the effectiveness of carbamazepine. Double-blind study vs. placebo. Minerva Psichiatr 33:301\u2013304","journal-title":"Minerva Psichiatr"},{"key":"3048_CR103","first-page":"15","volume":"13","author":"H Vorma","year":"2011","unstructured":"Vorma H, Katila H (2011) Effect of valproate on benzodiazepine withdrawal severity in opioid-dependent subjects: a pilot study. Heroin Addict Relat Clin Probl 13:15\u201320","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"3048_CR104","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1177\/0269881117714050","volume":"31","author":"S Tamburin","year":"2017","unstructured":"Tamburin S, Faccini M, Casari R et al (2017) Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol 31:1369\u20131373. https:\/\/doi.org\/10.1177\/0269881117714050","journal-title":"J Psychopharmacol"},{"issue":"4","key":"3048_CR105","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eurpsy.2010.12.004","volume":"27","author":"J Bobes","year":"2010","unstructured":"Bobes J, Rubio G, Teran A et al (2010) Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry 27(4):301\u2013307. https:\/\/doi.org\/10.1016\/j.eurpsy.2010.12.004","journal-title":"Eur Psychiatry"},{"key":"3048_CR106","doi-asserted-by":"publisher","unstructured":"Pavlovic ZM (2010) Long-term treatment and relapse prevention of alcohol and benzodiazepine dependence with lamotrigine. J Neuropsychiatry Clin Neurosci. https:\/\/doi.org\/10.1176\/appi.neuropsych.22.2.247-q.e25","DOI":"10.1176\/appi.neuropsych.22.2.247-q.e25"},{"key":"3048_CR107","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/hup.497","volume":"18","author":"M Cheseaux","year":"2003","unstructured":"Cheseaux M, Monnat M, Zullino DF (2003) Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol 18:375\u2013377. https:\/\/doi.org\/10.1002\/hup.497","journal-title":"Hum Psychopharmacol"},{"key":"3048_CR108","unstructured":"Ansseau M, De Roeck J Trazodone in benzodiazepine dependence. J Clin Psychiatry 54:189\u2013191"},{"issue":"supl. 2","key":"3048_CR109","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1097\/00004714-199912002-00003","volume":"19","author":"K Rickels","year":"1999","unstructured":"Rickels K, DeMartinis N, Rynn M et al (1999) Pharmacologic strategies for discontinuation benzodiazepine treatment. J Psychopharmacol 19(supl. 2):12S\u201316S","journal-title":"J Psychopharmacol"},{"key":"3048_CR110","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1176\/ajp.143.12.1590","volume":"143","author":"E Schweizer","year":"1986","unstructured":"Schweizer E, Rickels K (1986) Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 143:1590\u20131592. https:\/\/doi.org\/10.1176\/ajp.143.12.1590","journal-title":"Am J Psychiatry"},{"issue":"1","key":"3048_CR111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-198702000-00003","volume":"7","author":"M Lader","year":"1987","unstructured":"Lader M, Olajide D (1987) A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 7(1):11\u201315","journal-title":"J Clin Psychopharmacol"},{"key":"3048_CR112","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1192\/bjp.157.2.232","volume":"157","author":"CH Ashton","year":"1990","unstructured":"Ashton CH, Rawlins MD, Tyrer SP (1990) A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 157:232\u2013238. https:\/\/doi.org\/10.1192\/bjp.157.2.232","journal-title":"Br J Psychiatry"},{"key":"3048_CR113","first-page":"46","volume":"51","author":"H Udelman","year":"1990","unstructured":"Udelman H, Udelman D (1990) Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J Clin Psychiatry 51:46\u201350","journal-title":"J Clin Psychiatry"},{"key":"3048_CR114","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004714-199804000-00004","volume":"18","author":"MK Romach","year":"1998","unstructured":"Romach MK, Kaplan HL, Busto UE et al (1998) A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. Clin Psychopharmacol 18:121\u2013131","journal-title":"Clin Psychopharmacol"},{"key":"3048_CR115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1192\/bjp.168.4.457","volume":"168","author":"P Tyrer","year":"1996","unstructured":"Tyrer P, Ferguson B, Hallstrom C et al (1996) A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br J Psychiatry 168:457\u2013461","journal-title":"Br J Psychiatry"},{"key":"3048_CR116","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1440-1819.2006.01565.x","volume":"60","author":"M Nakao","year":"2006","unstructured":"Nakao M, Takeuchi T, Nomura K et al (2006) Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry Clin Neurosci 60:605\u2013610","journal-title":"Psychiatry Clin Neurosci"},{"key":"3048_CR117","first-page":"e166","volume":"49","author":"PK Chandrasekaran","year":"2008","unstructured":"Chandrasekaran PK (2008) Employing mirtazapine to aid benzodiazepine withdrawal. Singap Med J 49:e166\u2013e167","journal-title":"Singap Med J"},{"key":"3048_CR118","first-page":"24","volume":"163","author":"Y Lecrubier","year":"2005","unstructured":"Lecrubier Y, Fessard N (2005) Stopping benzodiazepines in chronicle consumers: a double blind placebo controlled study vs gluconate de lithium. Ann Med Psychol 163:24\u201329","journal-title":"Ann Med Psychol"},{"key":"3048_CR119","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1527-3458.2004.tb00023.x","volume":"10","author":"M Bourin","year":"2004","unstructured":"Bourin M, Dailly E, Hasc\u00f6et M (2004) Preclinical and clinical pharmacology of Cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev 10:209\u2013219. https:\/\/doi.org\/10.1111\/j.1527-3458.2004.tb00023.x","journal-title":"CNS Drug Rev"},{"issue":"suppl. 1","key":"3048_CR120","first-page":"S53","volume":"5","author":"L Shukla","year":"2014","unstructured":"Shukla L, Kandasamy A, Kesavan M et al (2014) Baclofen in the short term maintenance treatment of benzodiazepine dependence. J Neurosci Rural Pract 5(suppl. 1):S53\u2013S54","journal-title":"J Neurosci Rural Pract"},{"key":"3048_CR121","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.phrs.2015.08.016","volume":"109","author":"DP Cardinali","year":"2016","unstructured":"Cardinali DP, Golombek DA, Rosenstein RE et al (2016) Assessing the efficacy of melatonin to curtail benzodiazepine\/Z drug abuse. Pharmacol Res 109:12\u201323 https:\/\/doi.org\/10.1016\/j.phrs.2015.08.016","journal-title":"Pharmacol Res"},{"key":"3048_CR122","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0140-6736(81)92861-0","volume":"1","author":"P Tyrer","year":"1981","unstructured":"Tyrer P, Rutherford D, Huggett T (1981) Benzodiazepine withdrawal symptoms and propranolol. Lancet 1:520\u2013522","journal-title":"Lancet"},{"key":"3048_CR123","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","volume":"30","author":"SA Steenen","year":"2016","unstructured":"Steenen SA, Wijk AJ, Van Der Heijden GJ (2016) Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol 30:128\u2013139","journal-title":"J Psychopharmacol"},{"key":"3048_CR124","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/ajp.143.7.900","volume":"143","author":"WK Goodman","year":"1986","unstructured":"Goodman WK, Charney DS, Price LH et al (1986) Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry 143:900\u2013903. https:\/\/doi.org\/10.1176\/ajp.143.7.900","journal-title":"Am J Psychiatry"},{"key":"3048_CR125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02246214","volume":"117","author":"E Schweizer","year":"1995","unstructured":"Schweizer E, Case WG, Garcia-Espana F et al (1995) Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology 117:424\u2013429","journal-title":"Psychopharmacology"},{"key":"3048_CR126","first-page":"469","volume":"24","author":"EG Hantouche","year":"1998","unstructured":"Hantouche EG, Guelfi JD, Comet D (1998) Alpha-beta L-aspartate magnesium in treatment of chronic benzodiazepine abuse: controlled and double-blind study versus placebo. Encephale 24:469\u2013479","journal-title":"Encephale"},{"key":"3048_CR127","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199120060-00001","volume":"20","author":"TM Ludden","year":"1991","unstructured":"Ludden TM (1991) Non-linear pharmacokinetics. Clin Pharmacokinet 20:429\u2013446. https:\/\/doi.org\/10.2165\/00003088-199120060-00001","journal-title":"Clin Pharmacokinet"},{"key":"3048_CR128","doi-asserted-by":"crossref","unstructured":"Moody DE (2012) Drug interactions with benzodiazepines: epidemiologic correlates with other CNS depressants and in vitro correlates with inhibitors and inducers of cytochrome P450 3A4. In: Handbook of drug interactions. A clinical and forensic guide. Mozayani a, Raymon L (eds) Humana Press, pp 25-118","DOI":"10.1007\/978-1-61779-222-9_2"},{"issue":"6","key":"3048_CR129","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bcp.12294","volume":"77","author":"R L\u00e4hteenm\u00e4ki","year":"2014","unstructured":"L\u00e4hteenm\u00e4ki R, Puustinen J, Vahlberg T et al (2014) Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol 77(6):975\u2013985","journal-title":"Br J Clin Pharmacol"},{"key":"3048_CR130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.1360-0443.2002.00129.x","volume":"97","author":"H Vorma","year":"2002","unstructured":"Vorma H, Naukkarinen H, Sarna H et al (2002) Treatment of out-patients with 1complicated benzodiazepine dependence: comparison of two approaches. Addiction 97:851\u2013859","journal-title":"Addiction"},{"key":"3048_CR131","doi-asserted-by":"crossref","unstructured":"Storhaug LW, Enger A, Hjelmeland K et al Prolonged excretion of 7-aminoclonazepam in urine after repeated ingestion of clonazepam: a case report. Forensic Sci Int 222:e33\u2013e35","DOI":"10.1016\/j.forsciint.2012.06.018"},{"issue":"9","key":"3048_CR132","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002881","volume":"95","author":"I Kacirova","year":"2016","unstructured":"Kacirova I, Grundmann M, Silhan P et al (2016) A case report of clonazepam dependence: utilization of therapeutic drug monitoring during withdrawal period. Medicine (Baltimore) 95(9):e2881. https:\/\/doi.org\/10.1097\/MD.0000000000002881","journal-title":"Medicine (Baltimore)"},{"key":"3048_CR133","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/08039481003624173","volume":"64","author":"B Vikander","year":"2010","unstructured":"Vikander B, Koechling UM, Borg S et al (2010) Benzodiazepine tapering: a prospective study. Nord J Psychiatry 64:273\u2013282. https:\/\/doi.org\/10.3109\/08039481003624173","journal-title":"Nord J Psychiatry"},{"issue":"10","key":"3048_CR134","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/00005053-197910000-00010","volume":"167","author":"F Miller","year":"1979","unstructured":"Miller F, Nulsen J (1979) SIngle case study. Diazepam (Valium) detoxification. J Nerv Ment Dis 167(10):637\u2013638. https:\/\/doi.org\/10.1097\/00005053-197910000-00010","journal-title":"J Nerv Ment Dis"},{"key":"3048_CR135","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/FTD.0000000000000174","volume":"37","author":"K Nordal","year":"2015","unstructured":"Nordal K, \u00d8iestad EL, Enger A et al (2015) Detection ties of diazepam, clonazepam, and alprazolam in oral fluid collected from patients aditted to detoxification, after high and repeated drug intake. Ther Drug Monit 37:451\u2013460. https:\/\/doi.org\/10.1097\/FTD.0000000000000174","journal-title":"Ther Drug Monit"},{"key":"3048_CR136","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/bmj.291.6497.688","volume":"291","author":"AC Higgitt","year":"2009","unstructured":"Higgitt AC, Lader MH, Fonagy P (2009) Clinical management of benzodiazepine dependence. Br Med J 291:688\u2013690","journal-title":"Br Med J"},{"issue":"6","key":"3048_CR137","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00004714-198912000-00005","volume":"9","author":"UE Busto","year":"1989","unstructured":"Busto UE, Sykora K, Sellers EM (1989) A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 9(6):412\u2013416","journal-title":"J Clin Psychopharmacol"},{"key":"3048_CR138","unstructured":"Microgenics Corporation (2012) DRI\u00ae benzodiazepine serum Tox assay (package insert). Fremont, USA"},{"key":"3048_CR139","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jat\/32.6.433","volume":"32","author":"RT DeRienz","year":"2008","unstructured":"DeRienz RT, Holler JM, Manos ME et al (2008) Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine. J Anal Toxicol 32:433\u2013437","journal-title":"J Anal Toxicol"},{"key":"3048_CR140","first-page":"359","volume":"17","author":"A Darragh","year":"2014","unstructured":"Darragh A, Snyder ML, Ptolemy AS et al (2014) KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain. Pain Physician 17:359\u2013366","journal-title":"Pain Physician"},{"key":"3048_CR141","first-page":"133","volume":"25","author":"F Jung","year":"1997","unstructured":"Jung F, Richardson TH, Raucy JL et al (1997) Diazepam metabolism by cDNA-expressed human 2C P450s. Identification of P4502C18 and P4502C19 as low KM diazepam N-demethylases. Drug Metab Dispos 25:133\u2013139","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03048-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03048-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03048-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T14:05:54Z","timestamp":1621260354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03048-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":141,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3048"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03048-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability."}}]}}